Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Despite unprecedented disruptions caused globally by SARS-Cov-2, OUCRU has responded remarkably and addressed almost every important aspect of the pandemic, from its societal impact to viral genomic surveillance and COVID-19 therapy

Coronavirus artist illustration

Severe lockdowns and waves of infection have affected Viet Nam, Indonesia and Nepal over the last 18 months. However, alongside the disruption has come opportunity, particularly the opportunity to conduct research that helps understand the medical and social impact of the pandemic and improve the ways we control and treat the virus.

The virus has brought OUCRU together, when the virus seemed to threaten every aspect of life and work. The consequent research has been remarkable, not least because its conception and conduct has been in some of the most difficult circumstances any of us have ever experienced. Work has fostered new collaborations with respective governments and their institutions that have ensured our research is relevant and impactful. These collaborations will have a lasting effect on OUCRU’s standing and future work within the region.

Between July 2020 and August 2021, OUCRU carried out diverse Covid-19-related projects:

  • Randomised Controlled Trials
  • Observational Clinical Studies
  • Diagnostic & Laboratory Studies
  • Epidemiology & Modelling Studies
  • Social Science Studies
  • Public & Community Engagement
  • Policy Engagement

The full story is available on the OUCRU website

Download OUCRU Covid-19 Portfolio (2021)

Similar stories

The global burden of Plasmodium vivax malaria is obscure and insidious

Until recently, Plasmodium falciparum dominated the malaria research landscape, and Plasmodium vivax infection was considered benign and inconsequential. We now know that this is not true: if not properly diagnosed and treated, P. vivax can lead to life-threatening syndromes and death. Professor Kevin Baird from EOCRU in Jakarta, Indonesia talks to OutBreak News Today

Large-scale systematic review identifies research gaps in scrub typhus

A new, extensive systematic review has identified significant research gaps in the treatment of scrub typhus which could be improved by developing a database for individual participant data (IPD) to enable more detailed analyses to address important knowledge gaps such as the optimum dosing for children and to improve patient outcomes.

Tamoxifen repurposing study shows no benefit in treating deadly fungal meningitis

Hopes that tamoxifen could improve survival for a deadly form of fungal meningitis have been dashed by the results of a clinical trial conducted by University of Oxford researchers and published today in eLife.

Largest ever global study of tuberculosis identifies genetic causes of drug resistance

Using cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common tuberculosis drug treatments.

Second most common malaria parasite takes unrealized toll on human health

The malaria parasite Plasmodium vivax causes frequent, chronic infections that represent a major unrecognized burden on global health, according to a review by Kevin Baird of the Eijkman-Oxford Clinical Research Unit in Indonesia and Katherine Battle of the Institute for Disease Modeling in the United States

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include OUCRU in Vietnam and institutions in Canada, Chile, Australia and the UK. GPAS is also now part of the Public Health England New Variant Assessment Platform.